Zepbound is not covered by Medicare or many other insurance plans as a treatment for weight loss. The injectable treatment ...

There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

Nyxoah's disrupting Genio implant is likely to revolutionize Obstructive Sleep Apnea, and FDA's decision is expected in Q1 ...

Sleep apnoea is common among older adults but is often overlooked or ignored leading to delayed diagnosis and treatment ...

The Food and Drug Administration (FDA) on Dec. 20 approved the obesity medication Zepbound (tirzepatide) as the first pharmaceutical treatment for moderate-to-severe obstructive sleep apnea (OSA ...

Surgery is also an option. Two clinical trials showed Zepbound reduced the frequency of sleep apnea episodes, an improvement likely linked to patients' weight loss, the FDA said. "Nearly half of ...

"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally Seymour, MD, director of the Division of Pulmonology, Allergy, and Critical ...

U.S. regulators have approved the first drug treatment for sleep apnea, permitting the use of a weight-loss medication for the condition that affects millions of Americans. "This is a major step ...

GLP-1 receptor agonist drugs like Ozempic, Wegovy and Mounjaro have helped millions of Americans lose weight and better manage their type 2 diabetes. Now, new research suggests Eli Lilly's weight loss ...